Mario Guillen

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse, S. Oparil, Pankaj Gupta, 2022, The Lancet.